Biotech Values

[DewDiligence]

SHPG prevails against five challengers on US Vyvanse patent:

http://finance.yahoo.com/news/vyvanse-patents-found-infringed-valid-064400836.html

…the U.S. District Court for the District of New Jersey granted Shire's summary judgment motion in a patent infringement lawsuit, holding that certain claims of the patents protecting Vyvanse® (lisdexamfetamine dimesylate) were both infringed and valid.

The ruling prevents the five pharmaceutical manufacturers (the ANDA Defendants) who have filed Abbreviated New Drug Applications (ANDAs) from launching generic versions of Vyvanse until the earlier of either a successful appeal to the U.S. Court of Appeals for the Federal Circuit, or the expiration of these patents in 2023.

Vyvanse is SHPG’s flagship drug. This ruling may make the eventual buyout of SHPG even more likely than it already was.